Automation in value-based laboratory medicine: driving precision, capacity, and better outcomes
Clinical Snapshot
PICO Framework
| P — Population | Clinical laboratories and healthcare systems implementing laboratory automation |
| I — Intervention | Laboratory automation technologies including hyperautomation, digitalization, and artificial intelligence integration |
| C — Comparator | Traditional manual laboratory processes and isolated testing units |
| O — Outcomes | Clinical outcomes, operational efficiency, healthcare system sustainability, and value-based care delivery |
Bottom Line
This narrative review explores the evolution of laboratory automation toward value-based care delivery, highlighting expansion beyond traditional chemistry and immunoassays into molecular diagnostics and mass spectrometry. The authors propose that hyperautomation—integrating artificial intelligence and digitalization—transforms laboratories into integrated diagnostic hubs. While the concept is compelling and aligns with healthcare system needs for efficiency and precision medicine, the review lacks systematic methodology and quantitative evidence. Australian laboratories implementing automation should consider this framework within existing NPAAC standards and Medicare pathology reforms, but require more robust evidence on cost-effectiveness, implementation challenges, and patient outcomes before major system changes. The review serves as a useful conceptual foundation but should be supplemented with systematic reviews and implementation studies for evidence-based decision making.
Key Findings
Effect Size: Not quantified
Primary Outcome: Laboratory automation enhances clinical outcomes, operational efficiency, and healthcare system sustainability
Nnt Or Sensitivity: Not reported
Confidence Interval: Not provided
Clinical Application
Generally feasible for established laboratories with adequate infrastructure and resources Highly relevant to Australian pathology services under Medicare Benefits Schedule reforms and NPAAC accreditation requirements. Supports RACGP emphasis on evidence-based diagnostics and TGA regulatory framework for automated systems Clinical laboratories across all healthcare settings seeking to implement value-based care models
Abstract
Laboratory medicine lies at the core of modern healthcare, enabling timely diagnosis, effective patient monitoring, and increasingly personalized therapeutic strategies. Over the past decades, automation has profoundly reshaped the role of clinical laboratories, substantially enhancing their contribution to clinical outcomes, operational efficiency, and the overall sustainability of healthcare systems. More recently, laboratory automation has emerged as a cornerstone of value-based laboratory medicine, representing not merely a technological upgrade but a strategic transformation of laboratory practice aimed at delivering measurable value to patients and healthcare stakeholders. Although automation has long been established in clinical chemistry and immunoassays, its scope is now expanding to molecular diagnostics and mass spectrometry - two disciplines that are central to precision medicine. Looking ahead, the convergence of automation, digitalization, and artificial intelligence is driving the emergence of hyperautomation in laboratory medicine. Within this paradigm, laboratories evolve from isolated testing units into integrated diagnostic hubs, in which results from multiple laboratory disciplines are harmonized and contextualized to effectively support clinical decision-making.
References
- 1.Gruson, D., Zima, T., & Plebani, M. (2026). Automation in value-based laboratory medicine: driving precision, capacity, and better outcomes. Clinical Chemistry and Laboratory Medicine. https://doi.org/10.1515/cclm-2025-1733
Related Research
ACS biomaterials science & engineering
A Review of Biomass-Derived Nanomaterials as Functional Interfaces for Advanced Electrochemical Hormone Detection
14 July 2026
Analytica chimica acta
Rapid detection of drug-resistant leukemia cell using an optofluidic chip and machine learning
16 June 2026
Blood advances
FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.
9 June 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service